National Association for Proton Therapy establishes Physician Advisory Committee

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

To guide the National Association for Proton Therapy, the organization has created a Physician Advisory Committee.

The committee will advise NAPT on critical issues including advancing clinical research collaboration, patient education and equitable insurance reimbursement practices.

Chaired by J. Isabelle Choi, clinical director and research director of the New York Proton Center and Assistant Member at Memorial Sloan Kettering Cancer Center, the committee is comprised of national leaders in radiation oncology and proton therapy including:

  • Gopal Bajaj, Inova Schar Cancer Institute Proton Therapy Center,

  • Brian Baumann, S. Lee Kling Center for Proton Therapy at the Siteman Cancer Center,

  • Jeff Bradley, Emory Proton Therapy Center,

  • Andrew Chang, California Protons Cancer Therapy Center,

  • Steve Frank, MD Anderson Cancer Center Proton Therapy Center,

  • James Gray, Provision CARES Proton Therapy Center,

  • Brandon Gunn, MD Anderson Cancer Center Proton Therapy Center,

  • Nancy Mendenhall, University of Florida Health Proton Therapy Institute,

  • Minesh Mehta, Miami Cancer Institute Proton Therapy Center at Baptist Health South Florida,

  • Charles Simone, New York Proton Center,

  • Christina Tsien, The Johns Hopkins National Proton Center,

  • Torunn Yock, Francis Burr Proton Therapy Center at Massachusetts General Hospital,

  • Jing Zeng, Seattle Cancer Care Alliance Proton Therapy Center.

Under Choi’s leadership, the NAPT Physician Advisory Committee will promote the benefits of proton therapy. The committee will attend advocacy meetings with federal and state government agencies and members of Congress, collaborate with other cancer-related stakeholders, and support proton therapy research.

Previously, Choi was an assistant professor at the University of Maryland School of Medicine and served as a clinical lead of the Maryland Proton Treatment Center.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login